ANI Pharmaceuticals Announces FDA Approval and Launch of Isosorbide Mononitrate Tablet

Rhea-AI Summary

ANI Pharmaceuticals (Nasdaq: ANIP) announced FDA final approval and launch of Isosorbide Mononitrate Tablet USP, 10 mg and 20 mg on April 8, 2026. The product is the generic of reference listed drug Monoket. The company said the launch targets limited‑competition markets and reflects its R&D and operational capabilities.

Positive

• FDA final approval for ANDA on April 8, 2026
• Launched Isosorbide Mononitrate USP in 10 mg and 20 mg strengths
• Product is a generic of Monoket, targeting limited‑competition segment
• Company cited strengthened R&D and operational execution supporting launches

Negative

• None.

News Market Reaction – ANIP

-0.58%

-0.58% Session close to close

In the Apr 8 session, ANIP declined 0.58%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement adds another FDA-approved generic to ANI’s portfolio, with Isosorbide Mononitrate ...

Analysis

This announcement adds another FDA-approved generic to ANI’s portfolio, with Isosorbide Mononitrate Tablets USP in 10 mg and 20 mg strengths as a Monoket generic. It follows multiple recent FDA approvals and launches across different therapeutic areas, reinforcing a steady cadence of product introductions. Investors may watch how this limited-competition product contributes to overall revenue mix alongside prior launches and how consistently ANI maintains this approval tempo.

Key Figures

Dosage strength: 10 mg Dosage strength: 20 mg

2 metrics

Dosage strength 10 mg Isosorbide Mononitrate Tablet USP strength in FDA-approved ANDA

Dosage strength 20 mg Isosorbide Mononitrate Tablet USP strength in FDA-approved ANDA

Previous Fda approval Reports

5 past events · Latest: Mar 14 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 14	FDA label expansion	Positive	+1.7%	FDA approval to expand ILUVIEN label for additional uveitis indication.
Mar 03	FDA device format OK	Positive	+1.1%	FDA approval of new prefilled syringe format for Cortrophin Gel.
Jan 02	Generic launch CGT	Positive	+0.3%	FDA approval and launch of Prucalopride Tablets with 180-day CGT exclusivity.
Oct 25	Generic estradiol launch	Positive	-1.6%	FDA approval and launch of Estradiol Gel 0.06% in a $16.7M market.
Sep 26	Generic shampoo launch	Positive	+1.8%	FDA approval and launch of Ketoconazole Shampoo 2% for Nizoral market.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

FDA approvals have generally seen small positive next-day moves, with one notable negative reaction.

Recent Company History

Recent FDA-related news for ANI shows a consistent cadence of approvals and launches across ophthalmology, autoimmune, gastrointestinal, and dermatology products. Prior FDA approvals for ILUVIEN, Cortrophin Gel prefilled syringe, Prucalopride Tablets, Estradiol Gel 0.06%, and Ketoconazole Shampoo 2% produced mostly modest positive moves, typically within a few percent. The current Isosorbide Mononitrate generic approval and launch fits this pattern of incremental, product-specific catalysts supporting ANI’s broader portfolio strategy.

Key Terms

u.s. food and drug administration, fda, abbreviated new drug application, reference listed drug

4 terms

u.s. food and drug administration regulatory

"following final approval from the U.S. Food and Drug Administration (FDA) for its"

The U.S. Food and Drug Administration is the federal agency that evaluates and enforces safety, effectiveness and labeling standards for medicines, medical devices, vaccines, food and related products before they reach consumers. For investors it matters because FDA approvals, warnings or recalls determine whether a product can be sold, how quickly it reaches the market and how costly compliance will be—changes that directly affect a company’s revenue, costs and stock value.

fda regulatory

"following final approval from the U.S. Food and Drug Administration (FDA) for its"

The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.

abbreviated new drug application regulatory

"final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA)"

An abbreviated new drug application is a regulatory submission used to gain approval to market a generic version of an already approved prescription medicine by showing it is equivalent in effect and safety to the original product, without repeating full clinical trials. For investors, an approval signals a lower-cost competitor entering the market that can quickly capture sales from the branded drug, similar to a generic knock‑off replacing a name‑brand item on store shelves.

reference listed drug regulatory

"Tablet USP is the generic version of the reference listed drug (RLD) Monoket"

A reference listed drug is the approved, original version of a medicine that regulators use as the official “master copy” when evaluating generic versions for safety, strength and how the body absorbs it. For investors, the RLD determines what competitors must match to win approval, shaping how quickly lower‑priced generics can enter the market and therefore affecting future sales, pricing pressure and legal disputes over market exclusivity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PRINCETON, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched Isosorbide Mononitrate Tablet USP, 10 mg and 20 mg. ANI’s Isosorbide Mononitrate Tablet USP is the generic version of the reference listed drug (RLD) Monoket^®.

“We are pleased to announce FDA approval and launch of Isosorbide Mononitrate Tablet USP, which highlights our efforts to bring limited-competition products to market and ensure that our high-quality products are readily accessible to our customers and patients in need,” stated Nikhil Lalwani, President and Chief Executive Officer of ANI. “This launch reinforces the strength of our R&D capabilities and operational execution as well as our commitment to maintaining a steady cadence of new product launches.”

About ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives” by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit www.anipharmaceuticals.com.

Forward-Looking Statements

To the extent any statements made in this release relate to information that is not historical, these are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the Company’s strategy; its plans with respect to the commercialization and potential sales of the Company’s products, including the launch of Isosorbide Mononitrate Tablet, USP; its efforts to bring limited-competition products to market and ensure that is high-quality products are readily accessible to its customers and patients in need; expansion plans for the Company’s Rare Disease, Generics and Brands businesses; and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “plans,” “potential,” “future,” “believes,” “intends,” “continue,” the negatives thereof, or other words of similar meaning, derivations of such words and the use of future dates.

Uncertainties and risks may cause the Company’s actual results to be materially different than those expressed in or implied by such forward-looking statements. Uncertainties and risks include, but are not limited to: the ability of the Company’s approved products to achieve commercialization at levels of market acceptance that will allow the Company to maintain profitability; delays and disruptions in the production of the Company’s approved products; delays or failure to obtain or maintain approvals by the FDA of the Company’s products; changes in policy or actions that may be taken by the FDA, United States Drug Enforcement Administration and other regulatory agencies; risks that the Company may face with respect to importing raw materials and delays in delivery of raw materials and other ingredients and supplies necessary for the manufacture of the Company’s products from both domestic and overseas sources due to supply chain disruptions or for any other reason; the ability of the Company’s manufacturing partners to meet its product demands and timelines; the level of competition the Company faces and the legal, regulatory and/or legislative strategies employed by its competitors to prevent or delay competition from generic alternatives to branded products; the impact of legislative or regulatory reform on the pricing for pharmaceutical products; the Company’s ability, and that of its suppliers, development partners, and manufacturing partners, to comply with laws, regulations and standards that govern or affect the pharmaceutical and biotechnology industries; and general business and economic conditions, such as inflationary pressures and geopolitical conditions.

More detailed information on these and additional factors that could affect the Company’s actual results are described in the Company’s filings with the Securities and Exchange Commission (SEC), including its most recent annual report on Form 10-K and quarterly reports on Form 10-Q, and other periodic reports, as well as other filings with the SEC. All forward-looking statements in this news release speak only as of the date of this news release and are based on the Company’s current beliefs, assumptions, and expectations. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Relations:
Courtney Mogerley, Argot Partners
T: 646-368-8014
E: ani@argotpartners.com

Media Relations:
Argot Partners
T: 212-600-1494
E: ani@argotpartners.com

Source: ANI Pharmaceuticals, Inc.

FAQ

What did ANIP announce on April 8, 2026 regarding FDA approval?

ANI announced FDA final approval for an ANDA and the launch of Isosorbide Mononitrate USP. According to the company, approval enabled immediate commercial launch of 10 mg and 20 mg strengths as the generic of Monoket.

Which product did ANIP launch after FDA approval and what are the strengths?

ANI launched Isosorbide Mononitrate Tablet USP in 10 mg and 20 mg strengths. According to the company, these tablets are the generic version of the reference listed drug Monoket and are now commercially available.

How does the ANIP launch position the company in the market?

The launch targets limited‑competition product segments to improve access and market share. According to the company, this supports its strategy of steady new product introductions backed by R&D and operations.

Is Isosorbide Mononitrate by ANIP a new chemical entity or a generic for Monoket?

ANI’s product is a generic version of Monoket, not a new chemical entity. According to the company, the approval was granted via an ANDA and the product matches the reference listed drug.

When did ANI say the Isosorbide Mononitrate product became available for customers?

ANI announced the product launch on April 8, 2026, marking availability to customers and patients. According to the company, FDA final approval enabled immediate commercial release of the 10 mg and 20 mg tablets.

What did ANIP say about the significance of the Isosorbide Mononitrate launch?

The company described the launch as reinforcing its R&D and operational execution and commitment to access. According to the company, the approval and launch highlight focus on limited‑competition, high‑quality generics.